Soonyoung Park

O

Biomarker assays using plasma and extracellular vesicle (EV) samples to study immune responses

OHSU

Jan 2023 - Current (3 years 7 months)

Developed multiplex immunofluorescence (IF) and biomarker assays using plasma and extracellular vesicle (EV) samples to study immune responses. Utilized size exclusion chromatography and ultracentrifugation techniques to isolate and analyze EVs, ensuring high-quality samples for downstream applications. Conducted thorough patient data monitoring to correlate immune responses with treatment outcomes, particularly focusing on the effects of PARP inhibitors. Identified potential PARP inhibitor resistance markers through multiplex flow cytometry, selecting relevant immune markers for further analysis. Additionally, uploaded findings to the Cytec cloud for enhanced data management and collaboration, demonstrating adaptability in utilizing softwa

O

Replication stress induced by anti-tumor therapies

OHSU

Jan 2022 - Current (4 years 7 months)

As a researcher focused on replication stress induced by anti-tumor therapies, I utilized high-resolution microscopy and live cell imaging to detect and analyze the effects of various treatments. My work involved testing the cytotoxicity of Gemcitabine in pancreatic cancer, where I successfully identified replication stress levels using four distinct markers. I employed immunofluorescence techniques, including the conjugation of secondary antibodies, to enhance the accuracy of my findings. Additionally, I utilized flow cytometry to quantify cellular responses and applied my knowledge of molecular biology to interpret complex data. While managing a substantial volume of data, I leveraged Prisma Cloud for efficient file storage and collaborat

O

Multi-omics datasets (transcriptomics, proteomics, imaging)

OHSU

Aug 2018 - Dec 2023 (5 years 5 months)

Integrated multi-omics datasets (transcriptomics, proteomics, imaging) with AI-based analytics for biomarker-driven insights

O

Multiple drug candidates using cancer cell lines and in vivo efficacy models

OHSU

Aug 2018 - Current (8 years)

- Led collaborative oncology research projects with AstraZeneca to evaluate multiple drug candidates using cancer cell lines and in vivo efficacy models. - Conducted comprehensive cytotoxicity assays to assess the effects of drug candidates across various cancer types, ensuring robust data collection and analysis. - Utilized molecular biology techniques to identify unknown drug signaling pathways through transcriptome and proteomics analysis, enhancing our understanding of drug mechanisms. - Validated drug effects in multiple animal models, employing in vivo studies to confirm efficacy and safety. - Employed software development skills to streamline data analysis processes, while Microsoft 365 tools were utilized for project management

M

High-throughput screening and tumor microenvironment

M.D. Anderson Cancer Center

Oct 2013 - Apr 2018 (4 years 7 months)

Developed high-throughput screening and tumor microenvironment assays to study drug resistance in glioblastoma stem cells. This involved evaluating drugs used in other types of cancer for their efficacy against brain tumors, particularly due to the challenges posed by the blood-brain barrier. Employed high-throughput screening techniques to detect cytotoxic effects of these drugs on brain tumor stem cells, both in vitro and in vivo. Additionally, characterized the brain tumor microenvironment through immunofluorescence to assess immune infiltration, providing valuable insights into the tumor's response to therapeutic targets. While software development and Microsoft 365 were not directly relevant to this role, the analytical skills gained f

K

Immune response research on HIV T-cell

KNIH

Nov 2010 - Apr 2013 (2 years 6 months)

As a researcher focused on immune response mechanisms related to HIV T-cells, I led innovative studies aimed at understanding the intricacies of T-cell behavior and their role in the immune response. I developed and implemented epigenetic therapeutic strategies to enhance T-cell functionality. Additionally, I utilized software development skills to analyze complex data sets related to T-cell expansion and treatment with epigenetic drugs, ensuring precise tracking of experimental outcomes. Proficiency in Microsoft 365 facilitated effective documentation and collaboration within the research team, streamlining communication and project management throughout the research process.

About

Detail

Timeline

Résumé